Company: PTPI
Filing Date: 2025-02-13
Form Type: S-1/A
Source: 0001410578-25-000122
Chunk: 89

Company: Petros Pharmaceuticals, Inc.
Filing Date: 2025-02-13
Form: S-1/A
Chunk 89
---
| Net loss per common share                    | ​ | $                         | -16,008,578 | ​ | $           |  -5,137,132 | ​   | $                         |  -21,145,710 |
|                                              | ​ | ​                         |             | ​ | ​           |             | ​   | ​                         |              |
| Basic and Diluted                            | ​ | $                         |       -2.18 | ​ | ​           |             | ​   | $                         |        -2.88 |
| Weighted average common shares outstanding   | ​ | ​                         |             | ​ | ​           |             | ​   | ​                         |              |
| Basic                                        | ​ | ​                         |   7,332,030 | ​ | ​           |             | ​   | ​                         |    7,332,030 |
| Effects of common share equivalents          | ​ | ​                         |           — | ​ | ​           |             | ​   | ​                         |            — |
| Diluted                                      | ​ | ​                         |   7,332,030 | ​ | ​           |             | ​   | ​                         |    7,332,030 |

| (g) | The difference between the inventory and API value of $7.1 million and the collateral value of $2.0 million was treated as a loss on settlement with Vivus. |

50

### DESCRIPTION OF CAPITAL STOCK

#### General
The following description of our capital stock and provisions of our amended and restated certificate of incorporation (the “Articles of Incorporation”), and amended and restated by-laws (the “By-laws”) are summaries and are qualified by reference to the Articles of Incorporation and the By-laws that are on file with the SEC.

We do not currently have a sufficient number of authorized shares of common stock to cover the shares issuable upon the conversion of Series B Preferred Stock. As a result, before any shares of Series B Preferred Stock can become convertible, we need to receive stockholder approval of the Charter Amendment to sufficiently increase our authorized shares of common stock to cover the conversion of all outstanding shares of Series B Preferred Stock into common stock. We have agreed in the securities purchase agreement in connection with this offering to use our reasonable best efforts to obtain such approval within 60 days from the closing of this offering, and the Company agreed to cause an additional stockholder meeting to be held every ninety days thereafter until (i) such Stockholder Approval is obtained